Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Here’s what you can do to help boost your brain’s neurogenesis.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... hematopoietic stem cells (HSCs), and other target organs. Hemoglobinopathies and CASGEVY ...

Over the next 6 months, CrisprBits plans to introduce Novel applications of CRISPR in building iPSC (Induced pluripotent stem cells) models for rare diseases and targeted editing of cell lines and ...